CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to MIRM

Bulevirtide 2 mg and Brelovitug - 300 mg

Phase 3
Mirum Pharmaceuticals, Inc. (MIRM)

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Q2 '27
MIRMPhase 3

Bulevirtide 2 mg and Brelovitug - 300 mg Phase 3 Est. Readout

Bulevirtide 2 mg and Brelovitug - 300 mg
Q2 2027~QSTALE
CT.gov
00%
Competitive Landscape

0 competitors in Chronic Hepatitis D Infection

View Full Landscape
Drug Information

Target Indication

Chronic Hepatitis D Infection

Clinical Trial

NCT07200908

Last updated: 6/26/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.